Phase II Study of Erlotinib Plus Tivantinib (ARQ 197) in Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Just After Progression on EGFR-TKI, Gefitinib or Erlotinib
ESMO Open - United Kingdom
doi 10.1136/esmoopen-2016-000063
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2016
Authors
Publisher
BMJ